This is a preview of subscription content, log in via an institution to check access.
References
Kirchberger MC, Hauschild A, Schuler G, Heinzerling L (2016) Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer 65:182–184. https://doi.org/10.1016/j.ejca.2016.07.003
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/NEJMoa1504030
Lynch TJ, Bondarenko I, Luft A et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046–2054. https://doi.org/10.1200/JCO.2011.38.4032
Pfirschke C, Engblom C, Rickelt S et al (2016) Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44:343–354. https://doi.org/10.1016/j.immuni.2015.11.024
Pflugfelder A, Eigentler TK, Keim U et al (2011) Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. PLoS One 6:e16882. https://doi.org/10.1371/journal.pone.0016882
Ribas A, Kefford R, Marshall MA et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:616–622. https://doi.org/10.1200/JCO.2012.44.6112
Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526. https://doi.org/10.1056/NEJMoa1104621
Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Michael C. Kirchberger has received travel grants from Amgen, BMS, MSD, and Novartis, and received speaker fees from BMS. Bastian Schilling is on the advisory board or has received honoraria from Novartis, Roche, Bristol-Myers Squibb and MSD Sharp & Dohme, research funding from Bristol-Myers Squibb and MSD Sharp & Dohme and travel support from Novartis, Roche, Bristol-Myers Squibb and Amgen. Sebastian Haferkamp is on the advisory board or has received honoraria/travel support from Novartis, Roche, Amgen, Bristol-Myers Squibb and MSD Sharp & Dohme. Lucie Heinzerling has received speaker fees or acted as consultant for Amgen, BMS, MSD, Novartis and Roche. Anja Bosserhof and Gerold Schuler have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Rights and permissions
About this article
Cite this article
Kirchberger, M.C., Schilling, B., Haferkamp, S. et al. Can checkpoint inhibitor therapy improve response to chemotherapy?. J Cancer Res Clin Oncol 144, 183–185 (2018). https://doi.org/10.1007/s00432-017-2546-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-017-2546-8